Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue

Documenti analoghi

• Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
  di: Iskandar Idris
  Pubblicazione: (2024)
• Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
  di: Iskandar Idris
  Pubblicazione: (2024)
• Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
  di: Iskandar Idris
  Pubblicazione: (2024)
• Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
  di: Iskandar Idris
  Pubblicazione: (2024)
• Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
  di: Iskandar Idris
  Pubblicazione: (2024)